Drug Trial Radar · NCT07284602
Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)
Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,100
Planned (sponsor's estimate)
Start
Jun 26, 2026
Primary completion
Nov 2029
Study completion Dec 2029
Sponsor
- Lead sponsor
- PureTechIndustry
- Sponsor type
- Industry
- First posted
- Dec 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study for adults with a lung disease called idiopathic pulmonary fibrosis. The main purpose of this study is to look at how well deupirfenidone improves lung function and how safe it is for people with idiopathic pulmonary fibrosis (IPF) when compared with pirfenidone. Participants may have been treated with an approved antifibrotic drug for up to a year in the past, but they cannot be on background antifibrotic treatment during this study. Participants will be randomly assigned (meaning by chance) to take either deupirfenidone or pirfenidone 3 times a day, and neither a participant nor their study team will know which study drug participants are on. Participants will be in the study for up to approximately 3 years. During the first year, participants visit the study site up to ten times and afterwards they visit the site every three months. All participants will remain on blinded study drug until the last participant has completed Week 52 Visit. They will have lung function tests, a check of their health, and will tell the study team about any unfavorable effects.
Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
Interventions
DeupirfenidoneDrug
size AA Swedish orange capsule
Pirfenidone (PFD)Drug
size AA Swedish orange capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Absolute change in forced vital capacity (FVC) measured in mLTime frame: Baseline to Week 52
Locations
18 sites in 2 countries. Site status is shown where the registry gives one.
Palmtree Clinical Research Inc.
Palm Spring, California · Recruiting
Paradigm Clinical Research Centers LLC
Redding, California · Recruiting
Harmony Medical Research Institute, Inc
Hialeah, Florida · Recruiting
Clinical Research Specialists, LLC
Kissimmee, Florida · Recruiting
Infinity Medical Research
North Dartmouth, Massachusetts · Recruiting
Renown Regional Medical Center
Reno, Nevada · Recruiting
Pulmonix LLC
Greensboro, North Carolina · Recruiting
Clinical Research Associates of Central PA
DuBois, Pennsylvania · Recruiting
Clinical Research of Rock Hill
Rock Hill, South Carolina · Recruiting
Clinical Trials Center of Middle Tennesee LLC
Franklin, Tennessee · Recruiting
StatCare Pulmonary Consultants
Knoxville, Tennessee · Recruiting
Horizon Clinical Research Group.
Cypress, Texas · Recruiting
Premier Pulmonary Critical Care and Sleep Medicine
Denison, Texas · Recruiting
Renovatio Clinical
El Paso, Texas · Recruiting
Renovatio Clinical
The Woodlands, Texas · Recruiting
Renovatio Clinical
Webster, Texas · Recruiting
Dynamic Drug Advancement Limited
Ajax, Ontario, Canada · Recruiting
Dr. Syed Anees Medicine Professional Corporation
Windsor, Ontario, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.